share_log

Johnson & Johnson | 8-K/A: Johnson & Johnson Reports Q1 2024 Results (Amendment)

Johnson & Johnson | 8-K/A: Johnson & Johnson Reports Q1 2024 Results (Amendment)

強生 | 8-K/A：強生公布2024年第一季度業績(修正)
美股sec公告 ·  04/17 00:20
牛牛AI助理已提取核心訊息
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
Johnson & Johnson, a leading healthcare company, filed an amended Form 8-K/A with the SEC to correct a typographical error in their initial April 16, 2024, report. The correction adjusts the full-year April 2024 guidance for operational sales from $88.0 billion to $88.9 billion. The company announced its Q1 2024 results, reporting a 2.3% increase in sales to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, adjusted operational growth was 7.7%. First-quarter EPS rose to $2.20, with adjusted EPS increasing by 12.4% to $2.71. Johnson & Johnson also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The company's performance was driven by strong sales in its Innovative Medicine and MedTech segments, with notable growth in oncology, pulmonary hypertension, immunology, and neuroscience products. Additionally, the company highlighted several regulatory approvals, product launches, and acquisitions, emphasizing its commitment to innovation and leadership in healthcare.
領先的醫療保健公司強生公司向美國證券交易委員會提交了經修訂的8-K/A表格，以更正其2024年4月16日首次報告中的印刷錯誤。該修正將2024年4月全年營業銷售額預期從88億美元調整爲889億美元。該公司公佈了其2024年第一季度業績，銷售額增長2.3％，達到214億美元，運營增長3.9％，調整後的運營增長4.0％。不包括 COVID-19 疫苗，調整後的運營增長爲 7.7%。第一季度每股收益升至2.20美元，調整後的每股收益增長12.4％，至2.71美元。強生公司還提高了其2024年全年營業銷售額，並調整了運營每股收益預期。該公司的業績是由其創新醫學和醫療科技領域的強勁銷售推動的，腫瘤學、肺動脈高壓、免疫學和神經科學產品的顯著增長。此外，該公司還重點介紹了幾項監管批准、產品發佈和收購，強調了其對醫療保健領域創新和領導地位的承諾。
領先的醫療保健公司強生公司向美國證券交易委員會提交了經修訂的8-K/A表格，以更正其2024年4月16日首次報告中的印刷錯誤。該修正將2024年4月全年營業銷售額預期從88億美元調整爲889億美元。該公司公佈了其2024年第一季度業績，銷售額增長2.3％，達到214億美元，運營增長3.9％，調整後的運營增長4.0％。不包括 COVID-19 疫苗，調整後的運營增長爲 7.7%。第一季度每股收益升至2.20美元，調整後的每股收益增長12.4％，至2.71美元。強生公司還提高了其2024年全年營業銷售額，並調整了運營每股收益預期。該公司的業績是由其創新醫學和醫療科技領域的強勁銷售推動的，腫瘤學、肺動脈高壓、免疫學和神經科學產品的顯著增長。此外，該公司還重點介紹了幾項監管批准、產品發佈和收購，強調了其對醫療保健領域創新和領導地位的承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。